Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab

Trial ID # NCT03326193; OVARIO
Phase II
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Niraparib
Alternate Drug Names MK4827, Zejula
Drugs in Trial Carboplatin, Paclitaxel, Bevacizumab, Niraparib
Eligible Participant

Newly diagnosed high grade serous or endometrioid stage IIIb/IV ovarian cancer with CR or PR after first-line therapy

Patients Enrolled

105; 79% stage III, 63% w/ neoadjuvant chemotherapy

Therapy Setting


Study Design

Open-Label, Non-randomized


PFS, evaluated per RECIST


PFS: 19.6 months
PFS (HRD): 28.3 months
PFS (HRP): 14.2 months

PFS (6 months): 90%
PFS (12 months): 75%
PFS (18 months): 62%
PFS (24 months): 53%


Niraparib+bevacizumab maintenance treatment does not appear to cause cumulative toxicities and shows promising PFS


Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol (2022) 166(2):219-229

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.